Fall Savings30% off everything · Code:

Peptide

ARA-290

Name: ARA-290
Brand: Ventra Sciences
Availability: OutOfStock

CAS 1208243-50-8Research Use Only

A non-erythropoietic 11-amino-acid peptide engineered from erythropoietin, studied for its role in innate repair receptor (IRR) signaling and neuroimmune research. For laboratory research use only.

~~$65~~$45.50WITH CODE FALL

Dosage

Quantity

$65.00

Bundle & save

Free priority shipping on $250+

Third-party tested

U.S.-synthesized & shipped

Discreet packaging

Secure checkout

Card fields are hosted by our payment provider, so card numbers are never received or stored by Ventra. Apple Pay, Google Pay and Link are also available at checkout.

Compound Information

Technical specifications

Molecular Profile

What is this compound?

ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin, supplied as a lyophilized powder for in vitro laboratory research use only. It is engineered to engage the innate repair receptor (EPOR-beta common receptor complex) without erythropoietic activity, and appears in the peer-reviewed literature in studies of tissue-repair signaling, neuroimmune pathways, and small-fiber research models.

Research applications: Commonly used in innate repair receptor signaling studies, neuroimmune research, and tissue-repair pathway research applications.

Type: Non-erythropoietic erythropoietin-derived peptide
CAS Number: 1208243-50-8
Molecular Weight: 1257.3 g/mol
Formula: C51H84N16O21
Amino Acids: 11
Sequence: Erythropoietin helix-B-derived 11-mer

PubChem Database

Storage Requirements

Stability Information

Protect from lightTemperature-sensitive

Lyophilized (powder)-20°C · stable long-term

Reconstituted2-8°C · use within 28 days

Sources & References

Peer-reviewed research

Toxicology in Vitro

An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress

2020PMID 32335150DOI 10.1016/j.tiv.2020.104864

Shokrzadeh M, Etebari M, Ghassemi-Barghi N

View on PubMed

Pharmacology & Therapeutics

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin

2015PMID 25728128DOI 10.1016/j.pharmthera.2015.02.005

Collino M, Thiemermann C, Cerami A, et al.

View on PubMed

Frontiers in Immunology

Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice

2022PMID 36211426DOI 10.3389/fimmu.2022.1010882

Dennhardt S, Pirschel W, Wissuwa B, et al.

View on PubMed

References are provided for qualified researchers as a starting point for literature review. Ventra Sciences makes no claims about the contents of cited works.

For research use only

This product is intended strictly for in vitro laboratory research by qualified professionals. It is not for human or veterinary use and must not be used in food, drugs, diagnostics, or cosmetics. Ventra Sciences makes no medical claims regarding any compound sold. All purchasers acknowledge they will use this product solely for research purposes.

This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must comply with applicable institutional, local, and federal regulations.

By purchasing from Ventra Sciences, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance.